10-K Decoder · All companies

Aquestive Therapeutics, Inc.

AQST · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$44.5M$57.6M−22.6%
Operating income−$71.0M−$30.8M−131%
Net income−$83.8M−$44.1M−89.8%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026

$Q3 2026Year earlierChange
Revenue$7.60M$12.8M−40.6%
Operating income−$14.5M−$11.5M−26.1%
Net income−$16.5M−$15.4M−7.1%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Aquestive's revenue in FY2025?
$44.5M in FY2025 (Fiscal year ended Dec 31, 2025), −22.6% vs $57.6M a year earlier, per its 10-K filed Mar 2026.
Was Aquestive profitable in FY2025?
No: net income was −$83.8M and operating income −$71.0M in FY2025.
What was Aquestive's revenue in Q3 2026?
$7.60M (−40.6% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.